Member Info for VanVan

Seems do’able.

Wow those are some grades from loose samples -
But even the standard stuff looks great. Many Mines would give their right arm for grades like ours. As Kerim says it could be a high grade feed to the Kiziltepe mine.
I guess the Feasibility Study will be completed mid year given they are only 25% through the drill programme. I like the idea of a Toll Treatment Agreement rather than three times costs. Perhaps that will prove a better route with us retaining control of the asset.
Although I want share capital to be used to bring Tavsan on stream, the increase the Red Rabbit Resource & Life of Mine, to increase production capacity at Kiziltepe, and progress Salinbas, they are obviously looking to the future when they will pay dividends to shareholders. That will of course increase the stocks attraction. There is so much wealth creation capability here and we are still only just at first camp.

Just to clarify it was Biggles who spoke to Michael, not me on this occasion. Biggles then posted on ADVFN. I know Biggles quite well. He works in the Investment business and was invited to visit the mine last year during the Analyst visit. He holds just under 3% of the shares. He is a reliable source of information. His reports back from his visit posted on ADVFN at the time, were most encouraging.
It is worth following the Co. Twitter as they use that medium quite often.
As I understand they are in the Arzu pit area.
On Twitter it said:- "Arzu South Pit at its southern end - super progress!" AND "NW end of the Arzu South Pit at Kiziltepe today. High grades (>6g/t Au) being encountered along the vein (lighter colour linear feature) at bottom of pit"

I'm sure we will get an RNS confirming the director purchases and perhaps latest drill feedback in duel course. Kerim also going to do a Web cast with Andrew - Proactive Investments soon.

I’ve just spoken to michael DV . There is absolutely no problem with cash. The directors will buy the shares at current price not 1.48. There intention is not to drip feed into the market and they whole heartedly believe in the story and to back this up he said no current director has sold any shares or intends to do so. It was purely an accounting issue. They were advised incorrectly. He also sounded exceptionally excited about the prospects of existing pit which is where he was when I spoke to him 20 mins ago but could not elaborate. My take was they are finding some very good if no exceptional grades. So from horses mouth everything still on track , no problem with cash an accounting technicality , shares will be purchased and intention is to build up shareholding and not drip feed back into market.

John I’m 100% certain the first half of your post is correct. It’s nothing to do with actual cash.
I think you need a resolution at any AGM or like to change the capital account after years of incurred losses.
No big deal but William Payne as a supposed professional Accountant should know this.
But really of no consequence and I see nothing more than a bit of human error.
Chill

Storm in a tea cup imo. A human error that has been corrected by Directors purchasing.
The Nomad probably picked it up but the FD cocked up imo.
But nothing of significance. A minor blip. Lesson learnt. Move on.
Reassuring pictures on twitter tonight.

More photos on twitter:- Push-back underway on next phase of the Arzu South Pit at its southern end - super progress! #AAU #gold #mine

Twitter & photo:-
underway on next phase of the Arzu South Pit at its southern end - super progress! #AAU #gold #mine

Thanks for all that.
I'm aware that BioNTech and Genentech (part of Roche Group) are running Personalised Cancer Vaccine (PCV) trials where the blood & biopsy is sent away to the BioNTech German lab. to be re-engineered using computers and algorithms before being re-injected into the patients bloodstream. This is then stimulated with the Genentech immunotherapy drug know as Atezolizumab or sometimes called Tecentriq. This is a PDL-1 checkpoint inhibitor. I believe this is aimed at helping too get the T cells working as they should, killing the cancer cells. Isn't this even better than a global off the shelf vaccine like Modi1 from Scancell, or is the cost of a PCV just too expensive to make it commercially viable? I note the close links however between Scancell & BioNtech.
Hope you can help a novice!

We might start to attract a few specialised Institution Investors once were worth over £20m imo.
The chart also looks interesting, with my limited knowledge. If we can convert 1.75p from resistance to support I reckon the next leg up looks very possible. We've already had a golden cross.

Claret: Over many years I have followed all the big yielders. SUS, GVC and TEP over a 10 year period plus were all big multi baggers for me, but more recently have lost upward momentum . Also still great Co's though.
House builders have great yields (PSN, TW. etc.) but worries around a No deal BREXIT. And SSE yes.
I also like GAW, PLUS500 and 3i (3IN).
Central Asia Metals (CAML) is a nice yielder and should do well when copper recovers.
Anglo Asian Mining (AAZ) is a maiden yielder with no debt and one I like.
Evraz (EVR) is also a big yielder.
There are so many I could mention. Some I trade, others I hold for the long term. Ariana is a growth stock but I've been invested over 8 years. Average price c. 1p and at last making progress! Many yielders suffered recently but long term they tend to always recover as income stocks always find buyers!

I do both. Nice to invest for dividends as well as growth. Had some great performances doing that as well.

Fair summary but I’m not keen on these types of sites. One has to question if they are just punters like us, trying to convince subscribers it is worth the money. But your summary of AAU is a good one imo. Most AIM shares carry more than their fair share of risk, yet AAU is different. As you say it ticks the boxes that one would look for in a sensible investment. But being on AIM with a Market Cap. under £20m has so much upside potential. It would be difficult to find another AIM mining stock imo that does that. Please tell me if you know one!

I’m looking forward to news about Salinbas drill permits, recent Kiziltepe drill results and the impact on the Red Rabbit Resource. Guidance numbers aren’t far off either.
Although we might have to wait to Q4 , I’m also excitedly looking forward to the Tavsan build programme.
With the development loan pretty well dealt with this year it should be another transformational year.

Nor me John. A friend told me about it.

Good write up published

Did you hear John Meyer talk about SML & AAZ & Gold on Vox Markets yesterday. About 30 mins in.

Justin Waite Interviews John Meyer partner of SP Angel today about 30 minutes in. They discuss AAZ and SML plus John talks about gold.

Are you invested here in Avacta as well out of interest. Operating in similar fields.

I haven’t posted for a while but remain very encouraged by the potential.
Personal Cancer Vaccines like Modi-1 seem to be getting lots of energy behind them, but I’m also aware of the excitement around CART T - Adoptive Cell procedures. Do we have a view on which route will be the first to deliver a cancer cure, or is the Adoptive route too expensive given the white blood cells (T-Cells) have to be taken from the patient, then refrigerate and shipped to be reprogrammed using algorithms etc.Then frozen under liquid nitrogen before being transported back to the clinical site for infusion into the patient. But Co’s like Adaptimmune, Cell Medica , Autolus and Free Therapeutics are all focused on cancer I believe.
Any views please?